Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Tivic Health Systems ( (TIVC) ) is now available.
On January 20, 2026, Tivic Health Systems, Inc. announced it had made an investor presentation available on its website, outlining a clinical pipeline centered on its TLR5 agonist portfolio, led by Entolimod in late Phase III development for acute radiation syndromes and Entolasta in pre-clinical development for chronic radiation syndromes. The presentation highlights more than $140 million in prior investment, over 40 human and animal studies, extensive patent protection, and development funding from U.S. government agencies that are now positioned as key customer prospects, positioning Tivic to compete in the fast-growing global market for hematopoietic and gastrointestinal radiation treatments—currently dominated by G-CSF-based drugs and projected to reach $21.3 billion by 2032—while signaling multiple anticipated near-term value inflection points for stakeholders as the company advances its oncology and medical countermeasure programs.
The most recent analyst rating on (TIVC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Tivic Health Systems stock, see the TIVC Stock Forecast page.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The score is primarily held down by weak financial performance (tiny revenue base, persistent losses, and significant cash burn) and bearish technicals (price below all major moving averages with negative MACD). Partial offsets include strategic progress discussed on the earnings call and corporate steps to build manufacturing capability, but these come with added financing/dilution and execution risk.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc., listed on Nasdaq under the ticker TIVC, is a late-stage biologics company founded in 2016 that has pivoted since 2025 to focus on harnessing the immune system to treat radiation damage, oncology indications, and immune system disorders. With roughly 50 employees and integrated manufacturing, the company holds worldwide exclusive rights to a TLR5 agonist portfolio, including the recombinant proteins Entolimod and Entolasta, targeting acute and chronic radiation syndromes and related high-value medical countermeasure and oncology markets.
Average Trading Volume: 902,722
Technical Sentiment Signal: Sell
Current Market Cap: $3.08M
For detailed information about TIVC stock, go to TipRanks’ Stock Analysis page.